In experimental bleomycin-mediated lung fibrosis and unilateral obstructive nephropathy models, the treatment of Imatinib reduces the fibrogenesis via inhibiting fibroblast proliferation which is mediated by the c-abl activation through TGF-β [14,29]. Here, ABL1 is linked to pulmonary fibrosis.